639 related articles for article (PubMed ID: 19409666)
1. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
[TBL] [Abstract][Full Text] [Related]
2. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation.
Mori T; Okamoto S; Watanabe R; Yajima T; Iwao Y; Yamazaki R; Nakazato T; Sato N; Iguchi T; Nagayama H; Takayama N; Hibi T; Ikeda Y
Bone Marrow Transplant; 2002 May; 29(9):777-82. PubMed ID: 12040476
[TBL] [Abstract][Full Text] [Related]
3. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
[TBL] [Abstract][Full Text] [Related]
4. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
5. Prospective, comprehensive, and effective viral monitoring in children undergoing allogeneic hematopoietic stem cell transplantation.
Schönberger S; Meisel R; Adams O; Pufal Y; Laws HJ; Enczmann J; Dilloo D
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1428-35. PubMed ID: 20399877
[TBL] [Abstract][Full Text] [Related]
6. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
Solano C; Muñoz I; Gutiérrez A; Farga A; Prósper F; García-Conde J; Navarro D; Gimeno C
J Clin Microbiol; 2001 Nov; 39(11):3938-41. PubMed ID: 11682510
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir.
Razonable RR; van Cruijsen H; Brown RA; Wilson JA; Harmsen WS; Wiesner RH; Smith TF; Paya CV
J Infect Dis; 2003 Jun; 187(11):1801-8. PubMed ID: 12751039
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection.
Einsele H; Hebart H; Kauffmann-Schneider C; Sinzger C; Jahn G; Bader P; Klingebiel T; Dietz K; Löffler J; Bokemeyer C; Müller CA; Kanz L
Bone Marrow Transplant; 2000 Apr; 25(7):757-63. PubMed ID: 10745262
[TBL] [Abstract][Full Text] [Related]
9. Human cytomegalovirus (HCMV) replication kinetics in stem cell transplant recipients following anti-HCMV therapy.
Buyck HC; Griffiths PD; Emery VC
J Clin Virol; 2010 Sep; 49(1):32-6. PubMed ID: 20667769
[TBL] [Abstract][Full Text] [Related]
10. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load > or =10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients.
Verkruyse LA; Storch GA; Devine SM; Dipersio JF; Vij R
Bone Marrow Transplant; 2006 Jan; 37(1):51-6. PubMed ID: 16284613
[TBL] [Abstract][Full Text] [Related]
11. Failure of pre-emptive treatment of cytomegalovirus infections and antiviral resistance in stem cell transplant recipients.
van der Beek MT; Marijt EW; Vossen AC; van der Blij-de Brouwer CS; Wolterbeek R; Halkes CJ; Claas EC; Kroes AC
Antivir Ther; 2012; 17(1):45-51. PubMed ID: 22267468
[TBL] [Abstract][Full Text] [Related]
12. Comparison of antigenemia assay and semiquantitative polymerase chain reaction test for monitoring active cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
Pajand O; Ziyaeyan M; Mousavi S; Fatolahzadeh B; Hojabri Z; Bahador A; Abdossamadi Z
Exp Clin Transplant; 2008 Jun; 6(2):149-54. PubMed ID: 18816243
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the NucliSens CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation.
Hebart H; Rudolph T; Loeffler J; Middeldorp J; Ljubicic T; Jahn G; Einsele H
Bone Marrow Transplant; 2002 Aug; 30(3):181-7. PubMed ID: 12189537
[TBL] [Abstract][Full Text] [Related]
14. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
Bordon V; Bravo S; Van Renterghem L; de Moerloose B; Benoit Y; Laureys G; Dhooge C
Transpl Infect Dis; 2008 Feb; 10(1):19-23. PubMed ID: 17511814
[TBL] [Abstract][Full Text] [Related]
15. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T
Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
[TBL] [Abstract][Full Text] [Related]
16. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR.
Schulenburg A; Watkins-Riedel T; Greinix HT; Rabitsch W; Loidolt H; Keil F; Mitterbauer M; Kalhs P
Bone Marrow Transplant; 2001 Oct; 28(8):765-8. PubMed ID: 11781628
[TBL] [Abstract][Full Text] [Related]
17. Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.
Gerna G; Lilleri D; Zecca M; Alessandrino EP; Baldanti F; Revello MG; Locatelli F
Haematologica; 2005 Apr; 90(4):526-33. PubMed ID: 15820949
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M
Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310
[TBL] [Abstract][Full Text] [Related]
19. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
Alberú J; Morales-Buenrostro LE; Correa-Rotter R; Muñoz-Trejo T; Zúñiga-Varga J; Cuéllar-González JV; Mayorga-Madrigal H; Vanegas-Carrero R; Aranda F; Rodríguez-Romo R; Herrera-Garcia C; González-Michaca L; Sierra-Madero JG
Rev Invest Clin; 2008; 60(5):365-74. PubMed ID: 19227433
[TBL] [Abstract][Full Text] [Related]
20. Saliva as a source of HCMV DNA in allogeneic stem cell transplantation patients.
Correia-Silva JF; Bruna-Romero O; Resende RG; Miranda LP; Oliveira FE; Costa FO; Xavier SG; Figueiredo-Neves SP; Almeida HC; Bittencourt H; Gomez RS
Oral Dis; 2010 Mar; 16(2):210-6. PubMed ID: 20374507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
